KEYTRUDA® (Pembrolizumab) plus KISPLYX® (Lenvatinib) - First-Line Treatment of Patients with advanced Renal Cell Carcinoma

被引：0
|
作者：
不详
机构：
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2021年 / 44卷 / 1-2期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：70 / 70
页数：1
相关论文
共 50 条
  • [1] PHASE 3 STUDY OF PEMBROLIZUMAB plus BELZUTIFAN plus LENVATINIB OR PEMBROLIZUMAB/QUAVONLIMAB plus LENVATINIB VERSUS PEMBROLIZUMAB plus LENVATINIB AS FIRST-LINE TREATMENT FOR ADVANCED RENAL CELL CARCINOMA
    Choueiri, Toni
    Plimack, Elizabeth
    Powles, Thomas
    Voss, Martin
    Gurney, Howard
    Silverman, Rachel
    Perini, Rodolfo
    Rodriguez-Lopez, Karla
    Rini, Brian
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A447 - A447
  • [2] Phase 3 study of first-line treatment with pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib for advanced renal cell carcinoma (RCC).
    Choueiri, Toni K.
    Plimack, Elizabeth R.
    Powles, Thomas
    Voss, Martin H.
    Gurney, Howard
    Silverman, Rachel Kloss
    Perini, Rodolfo F.
    Rodriguez-Lopez, Karla
    Rini, Brian I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [3] Cost-Effectiveness of Lenvatinib Plus Pembrolizumab or Everolimus as First-Line Treatment of Advanced Renal Cell Carcinoma
    Wang, Ye
    Wang, Hao
    Yi, Manman
    Han, Zhou
    Li, Li
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
  • [4] Efficacy of pembrolizumab plus lenvatinib as first-line treatment for metastatic renal cell carcinoma with multiple brain metastases
    Matsumoto, Daisuke
    Naiki, Taku
    Naiki-Ito, Aya
    Aoki, Maria
    Kato, Shinji
    Morikawa, Toshiharu
    Shimizu, Nobuhiko
    Gonda, Masakazu
    Umemoto, Yukihiro
    Yasui, Takahiro
    [J]. IJU CASE REPORTS, 2024,
  • [5] Lenvatinib plus pembrolizumab as first-line therapy in patients with advanced renal cell carcinoma outside of clinical trials - results of a monocentric analysis
    Wullenkord, R.
    Heller, M.
    Ferber, D. S.
    Hoeper, C.
    Bochtler, T.
    Haag, G. M.
    Berger, A. K.
    Jaeger, D.
    Zschaebitz, S.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 320 - 321
  • [6] Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
    Motzer, Robert
    Alekseev, Boris
    Rha, Sun-Young
    Porta, Camillo
    Eto, Masatoshi
    Powles, Thomas
    Gruenwald, Viktor
    Hutson, Thomas E.
    Kopyltsov, Evgeny
    Mendez-Vidal, Maria J.
    Kozlov, Vadim
    Alyasova, Anna
    Hong, Sung-Hoo
    Kapoor, Anil
    Alonso Gordoa, Teresa
    Merchan, Jaime R.
    Winquist, Eric
    Maroto, Pablo
    Goh, Jeffrey C.
    Kim, Miso
    Gurney, Howard
    Patel, Vijay
    Peer, Avivit
    Procopio, Giuseppe
    Takagi, Toshio
    Melichar, Bohuslav
    Rolland, Frederic
    De Giorgi, Ugo
    Wong, Shirley
    Bedke, Jens
    Schmidinger, Manuela
    Dutcus, Corina E.
    Smith, Alan D.
    Dutta, Lea
    Mody, Kalgi
    Perini, Rodolfo F.
    Xing, Dongyuan
    Choueiri, Toni K.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (14): : 1289 - 1300
  • [7] Pembrolizumab (Keytruda) for First-Line Treatment of Metastatic NSCLC
    不详
    [J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2017, 59 (1513): : 4 - 5
  • [8] LEAP-014: first-line lenvatinib plus pembrolizumab plus chemotherapy in advanced/metastatic esophageal squamous cell carcinoma
    Sun, Jong-Mu
    Adenis, Antoine
    C Enzinger, Peter
    Shah, Manish A.
    Kato, Ken
    Bennouna, Jaafar
    Doi, Toshihiko
    Hawk, Natalyn Nicole
    Yu, Li
    Shah, Sukrut
    Bhagia, Pooja
    Shen, Lin
    [J]. FUTURE ONCOLOGY, 2024,
  • [9] LEAP-002: phase 3 study of first-line lenvatinib plus pembrolizumab for patients with advanced hepatocellular carcinoma
    Llovet, Josep
    Kudo, Masatoshi
    Cheng, Ann-Lii
    Finn, Richard
    Galle, Peter
    Kaneko, Shuichi
    Meyer, Tim
    Qin, Shukui
    Dutcus, Corina
    Chen, Erluo
    Dubrovsky, Leonid
    Siegel, Abby
    Zhu, Andrew
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [10] Re: Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
    Chang, Sam S.
    [J]. JOURNAL OF UROLOGY, 2021, 206 (06): : 1518 - 1519
12345